Evidence map›Paper›PMID 33026937›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021

Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model.

Inhye E Ahn, Xin Tian, David Ipe, Mei Cheng, Maher Albitar, L Claire Tsao, Lei Zhang, Wanlong Ma, Sarah E M Herman, Erika M Gaglione and 3 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 102 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. [Mechanism of BIM-induced ibrutinib resistance in chronic lymphocytic leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Observational
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Inhye E AhnHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0003-3717-287X
Xin TianOffice of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0003-1896-2462
David IpePharmacyclics LLC, an AbbVie Company, Sunnyvale, CA.
Mei ChengPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA.
Maher AlbitarNeoGenomics Laboratories, Irvine, CA.
L Claire TsaoPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA.
Lei ZhangPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA.
Wanlong MaNeoGenomics Laboratories, Irvine, CA.
Sarah E M HermanHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Erika M GaglioneHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0003-4831-3105
Susan SotoHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
James P DeanPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA.
Adrian WiestnerHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
National Institutes of Health · USAbbVie (United States) · USNeoGenomics (United States) · US

Funding

Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapyZIAHL002346 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI WIESTNER, ADRIAN U · 2009 to 2025
$29.8M
6 · The paper itself

Abstract

purposeRandomized trials established the superiority of ibrutinib-based therapy over chemoimmunotherapy in chronic lymphocytic leukemia. Durability of progression-free survival (PFS) with ibrutinib can vary by patient subgroup. Clinical tools for prognostication and risk-stratification are needed. PATIENTS AND

methodsPatients treated with ibrutinib in phase II and III trials provided the discovery data set and were subdivided into discovery and internal validation cohorts. An external validation cohort included 84 patients enrolled in our investigator-initiated phase II trial. Univariable analysis of 18 pretreatment parameters was performed using PFS and overall survival (OS) end-points. Multivariable analysis and machine-learning algorithms identified four factors for a prognostic model that was validated in internal and external cohorts.

resultsFactors independently associated with inferior PFS and OS were as follows:

conclusionPatients at increased risk of ibrutinib failure can be identified at treatment initiation and considered for clinical trials.

Indexed as

AdenineAdultAgedAged, 80 and overFemaleHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedPiperidinesPrognosisProgression-Free SurvivalTreatment OutcomeAdenineibrutinibPiperidines

Identifiers

PMID33026937
PMCPMC8189626
OpenAlexW3092160581

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.